Glaxosmithkline Plc Adr Stock Total Debt
GSK Stock | USD 39.60 0.35 0.88% |
GlaxoSmithKline PLC ADR fundamentals help investors to digest information that contributes to GlaxoSmithKline PLC's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline PLC stock.
GlaxoSmithKline |
GlaxoSmithKline PLC ADR Company Total Debt Analysis
GlaxoSmithKline PLC's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current GlaxoSmithKline PLC Total Debt | 18.02 B |
Most of GlaxoSmithKline PLC's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Competition |
Based on the latest financial disclosure, GlaxoSmithKline PLC ADR has a Total Debt of 18.02 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is significantly lower than that of the firm.
GlaxoSmithKline Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.GlaxoSmithKline PLC is currently under evaluation in total debt category among related companies.
GlaxoSmithKline Fundamentals
Return On Equity | 0.46 | ||||
Return On Asset | 0.0881 | ||||
Profit Margin | 0.16 % | ||||
Operating Margin | 0.20 % | ||||
Current Valuation | 173.83 B | ||||
Shares Outstanding | 2.04 B | ||||
Shares Owned By Institutions | 14.40 % | ||||
Number Of Shares Shorted | 4.83 M | ||||
Price To Earning | 11.80 X | ||||
Price To Book | 4.96 X | ||||
Price To Sales | 2.75 X | ||||
Revenue | 30.33 B | ||||
Gross Profit | 19.92 B | ||||
EBITDA | 9.29 B | ||||
Net Income | 4.93 B | ||||
Cash And Equivalents | 3.72 B | ||||
Cash Per Share | 0.32 X | ||||
Total Debt | 18.02 B | ||||
Debt To Equity | 0.98 % | ||||
Current Ratio | 1.43 X | ||||
Book Value Per Share | 3.29 X | ||||
Cash Flow From Operations | 6.35 B | ||||
Short Ratio | 1.83 X | ||||
Earnings Per Share | 2.99 X | ||||
Price To Earnings To Growth | 1.09 X | ||||
Target Price | 44.1 | ||||
Number Of Employees | 70.21 K | ||||
Beta | 0.27 | ||||
Market Capitalization | 83.68 B | ||||
Total Asset | 59.01 B | ||||
Retained Earnings | 7.24 B | ||||
Working Capital | (2.42 B) | ||||
Current Asset | 16.59 B | ||||
Current Liabilities | 13.42 B | ||||
Annual Yield | 0.04 % | ||||
Five Year Return | 5.32 % | ||||
Net Asset | 59.01 B | ||||
Last Dividend Paid | 0.58 |
About GlaxoSmithKline PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.